vs
INVESTORS TITLE CO（ITIC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
INVESTORS TITLE CO的季度营收约是RECURSION PHARMACEUTICALS, INC.的2.0倍（$69.5M vs $35.5M），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -1.6%），INVESTORS TITLE CO自由现金流更多（$25.4M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 14.0%）
该公司是全球首家产权保险公司，前身为费城房地产产权保险公司，目前专注于为房地产交易提供产权保险相关服务，保障房地产交易中产权方的合法权益，在产权保险领域拥有悠久的发展历史与行业积累。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ITIC vs RXRX — 直观对比
营收规模更大
ITIC
是对方的2.0倍
$35.5M
营收增速更快
RXRX
高出683.3%
-1.6%
自由现金流更多
ITIC
多$72.7M
$-47.3M
两年增速更快
RXRX
近两年复合增速
14.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $69.5M | $35.5M |
| 净利润 | — | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 13.8% | -304.8% |
| 净利率 | — | -304.2% |
| 营收同比 | -1.6% | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $3.97 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ITICRXRX
| Q4 25 | $69.5M | $35.5M | ||
| Q3 25 | $73.0M | $5.2M | ||
| Q2 25 | $73.6M | $19.2M | ||
| Q1 25 | $56.6M | $14.7M | ||
| Q4 24 | $70.6M | $4.5M | ||
| Q3 24 | $68.8M | $26.1M | ||
| Q2 24 | $65.4M | $14.4M | ||
| Q1 24 | $53.5M | $13.8M |
净利润ITICRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $12.2M | $-162.3M | ||
| Q2 25 | $12.3M | $-171.9M | ||
| Q1 25 | $3.2M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $9.3M | $-95.8M | ||
| Q2 24 | $8.9M | $-97.5M | ||
| Q1 24 | $4.5M | $-91.4M |
毛利率ITICRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率ITICRXRX
| Q4 25 | 13.8% | -304.8% | ||
| Q3 25 | 20.7% | -3327.6% | ||
| Q2 25 | 21.5% | -916.8% | ||
| Q1 25 | 7.2% | -1297.9% | ||
| Q4 24 | 15.3% | -4042.4% | ||
| Q3 24 | 16.8% | -377.1% | ||
| Q2 24 | 17.2% | -697.4% | ||
| Q1 24 | 10.8% | -698.4% |
净利率ITICRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 16.7% | -3135.3% | ||
| Q2 25 | 16.7% | -894.2% | ||
| Q1 25 | 5.6% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 13.5% | -367.5% | ||
| Q2 24 | 13.6% | -676.6% | ||
| Q1 24 | 8.5% | -662.4% |
每股收益（稀释后）ITICRXRX
| Q4 25 | $3.97 | $-0.17 | ||
| Q3 25 | $6.45 | $-0.36 | ||
| Q2 25 | $6.48 | $-0.41 | ||
| Q1 25 | $1.67 | $-0.50 | ||
| Q4 24 | $4.41 | $-0.56 | ||
| Q3 24 | $4.92 | $-0.34 | ||
| Q2 24 | $4.70 | $-0.40 | ||
| Q1 24 | $2.40 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.6M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $268.3M | $1.1B |
| 总资产 | $363.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ITICRXRX
| Q4 25 | $89.6M | $743.3M | ||
| Q3 25 | $110.8M | $659.8M | ||
| Q2 25 | $90.1M | $525.1M | ||
| Q1 25 | $81.7M | $500.5M | ||
| Q4 24 | $83.8M | $594.4M | ||
| Q3 24 | $112.9M | $427.6M | ||
| Q2 24 | $111.2M | $474.3M | ||
| Q1 24 | $135.0M | $296.3M |
总债务ITICRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益ITICRXRX
| Q4 25 | $268.3M | $1.1B | ||
| Q3 25 | $278.0M | $1.0B | ||
| Q2 25 | $266.2M | $919.1M | ||
| Q1 25 | $254.4M | $933.9M | ||
| Q4 24 | $251.8M | $1.0B | ||
| Q3 24 | $271.3M | $524.6M | ||
| Q2 24 | $261.8M | $584.4M | ||
| Q1 24 | $254.0M | $401.2M |
总资产ITICRXRX
| Q4 25 | $363.1M | $1.5B | ||
| Q3 25 | $363.3M | $1.4B | ||
| Q2 25 | $345.8M | $1.3B | ||
| Q1 25 | $333.8M | $1.3B | ||
| Q4 24 | $333.6M | $1.4B | ||
| Q3 24 | $352.0M | $726.5M | ||
| Q2 24 | $340.3M | $775.9M | ||
| Q1 24 | $329.5M | $557.8M |
负债/权益比ITICRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.9M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $25.4M | $-47.3M |
| 自由现金流率自由现金流/营收 | 36.5% | -133.1% |
| 资本支出强度资本支出/营收 | 8.0% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $47.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流ITICRXRX
| Q4 25 | $30.9M | $-46.1M | ||
| Q3 25 | $17.2M | $-117.4M | ||
| Q2 25 | $8.9M | $-76.4M | ||
| Q1 25 | $-75.0K | $-132.0M | ||
| Q4 24 | $29.8M | $-115.4M | ||
| Q3 24 | $7.8M | $-59.2M | ||
| Q2 24 | $8.4M | $-82.2M | ||
| Q1 24 | $1.4M | $-102.3M |
自由现金流ITICRXRX
| Q4 25 | $25.4M | $-47.3M | ||
| Q3 25 | $15.8M | $-117.6M | ||
| Q2 25 | $7.3M | $-79.6M | ||
| Q1 25 | $-1.4M | $-133.8M | ||
| Q4 24 | $22.4M | $-116.7M | ||
| Q3 24 | $6.1M | $-63.8M | ||
| Q2 24 | $6.3M | $-83.4M | ||
| Q1 24 | $-793.0K | $-109.0M |
自由现金流率ITICRXRX
| Q4 25 | 36.5% | -133.1% | ||
| Q3 25 | 21.7% | -2272.5% | ||
| Q2 25 | 9.9% | -413.9% | ||
| Q1 25 | -2.5% | -907.4% | ||
| Q4 24 | 31.7% | -2567.7% | ||
| Q3 24 | 8.8% | -244.6% | ||
| Q2 24 | 9.7% | -578.5% | ||
| Q1 24 | -1.5% | -789.9% |
资本支出强度ITICRXRX
| Q4 25 | 8.0% | 3.5% | ||
| Q3 25 | 1.8% | 4.7% | ||
| Q2 25 | 2.1% | 16.4% | ||
| Q1 25 | 2.4% | 12.4% | ||
| Q4 24 | 10.5% | 28.6% | ||
| Q3 24 | 2.5% | 17.5% | ||
| Q2 24 | 3.2% | 8.2% | ||
| Q1 24 | 4.2% | 48.2% |
现金转化率ITICRXRX
| Q4 25 | — | — | ||
| Q3 25 | 1.40× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | -0.02× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.95× | — | ||
| Q1 24 | 0.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
